The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Stay up to date on Biogen analyst ratings. Delving into Biogen's Background Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer ...

based biotechnology firm Biogen Idec. In March, Thomas Bucknum, the company's chief counsel, resigned following reports that he had sold stock in the firm just as potential safety problems with the ...

The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...

Biogen Idec's alpha V beta 6 integrin inhibitor STX-100 and FibroGen's connective tissue growth factor (CTGF) blocker FG-3019. Pharma's interest in fibrosis stems from the realisation that so many ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...